FinscoFinsco

Allogene Therapeutics (US.ALLO)

Capital Allocation Audit · Period: 2018 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.ALLO · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion100.1%→
ROE-15.3%→
Cash Conversion-→
D/E Ratio0.26↓
Gross Margin-→
US.ALLO (Allogene Therapeutics) | YoY: 2026 Q1 vs 2025 Q1


Metric            Value  YoY
----------------------------
FCF Conversion   100.1%    →
ROE              -15.3%    →
Cash Conversion       -    →
D/E Ratio          0.26    ↓
Gross Margin          -    →
Key Metrics
US.ALLO (Allogene Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
----------------------------
FCF Conversion 100.1% →
ROE -15.3% →
Cash Conversion - →
D/E Ratio 0.26 ↓
Gross Margin - →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies